Background {#Sec1}
==========

The widely accepted research definition of heavy menstrual bleeding (HMB) is menstrual blood loss exceeding 80 mL per menstrual period \[[@CR1]\]. Regular blood loss of this magnitude leads to considerable adverse impact on a woman's iron metabolism, incidence of iron deficiency and anaemia, as well as general health issues and her functioning in society \[[@CR2]\]. The impact HMB has on a woman's quality of life (QoL) can be a significant motivation for seeking medical help. Most sufferers seek simple measures for management and may initially avoid attendance at general practitioners or medical specialists \[[@CR1]--[@CR3]\]. Many have concern that major surgery may be required to manage their problem, and wish to avoid this.

HMB accounts for considerable morbidity in women of reproductive age and can greatly affect many aspects of their health and quality of life. This includes problems of length and heaviness of bleeding, severity of menstrual pain, problems with flooding and clots, problems with soiling, being confined to bed, mood changes, severe lethargy and fatigue, anxiety, psychiatric morbidity, iron deficiency and anaemia \[[@CR4]--[@CR11]\]. Around half of all women presenting with HMB have no evidence of underlying structural pelvic pathology (i.e. these are women with AUB-E (primary endometrial), AUB-O (primarily ovulatory disturbances) or AUB-C (coagulopathies) according to the FIGO PALM-COEIN classification of causes of HMB \[[@CR12]\]). These women may be particularly suitable for medical treatment with only limited initial investigations.

Epidemiological evidence has suggested that as many as 52% of all women at some point exhibit HMB symptoms. A recent survey conducted in five European countries found that among 1225 women, 27% of the respondents currently exhibited at least two predetermined symptoms suggestive of HMB \[[@CR13]\]. Many women affected by HMB do not seek medical help, and few of those who do consult physicians report that they have received appropriate effective treatment. HMB continues to be under-diagnosed and poorly treated \[[@CR13]\]. There is a real need for highly effective and simple measures. A novel combined oral contraceptive pill (COCP) with simple regimen and highly effective HMB suppression is greatly needed.

Objective or semi-objective measurement of blood loss is not practical in routine clinical practice; therefore, clinical evaluation of the symptom of HMB relies heavily on self-reporting, reflecting the subjective experience of individual women in the absence of any absolute reference point. Therefore, there has been a move recently to define HMB in clinical practice settings in terms of its impact on a woman's physical, emotional, social and material quality of life rather than on any current objective measure \[[@CR6]\]. This means that, in addition to management of iron deficiency, any active therapy must also aim for improvement of QoL measures.

In women with no underlying structural pathology, medical therapy is considered the preferred treatment for HMB \[[@CR14]\]. However, in order to determine the efficacy of a new treatment, it is necessary to measure the actual physical monthly blood loss both prior to and during treatment. In order to achieve reliable measurement of menstrual blood loss, women are required to collect all their soiled sanitary protection as well as ensure none is lost into the toilet or shower \[[@CR15], [@CR16]\]. This is extremely onerous especially as most women are now in full time work and must continue their menstrual blood collections at their workplace, a prospect that many women find daunting. This contributes to making modern-day recruitment of subjects difficult.

The main objective of this open-label pilot study was to determine the potential efficacy of a monophasic oestradiol-17β-nomegestrol acetate (E~2~/Nomac) combined oral contraceptive pill on measured menstrual blood loss in 12 women with objectively demonstrated HMB (greater than 80 mL of blood loss per cycle).

A secondary objective was to determine how feasible it would be to recruit for a larger placebo-controlled study of this oestradiol-17β-based COCP treatment, if the treatment appeared to be efficacious.

Methods {#Sec2}
=======

Inclusion criteria {#Sec3}
------------------

Women aged 18--50 who demonstrated heavy menstrual blood loss (MBL) greater than 80 mL in at least two of three regular menstrual periods during the pre-treatment phase and no significant uterine pathology on pelvic ultrasound were eligible to enter the treatment phase of the study. Hence, these women were likely to fit into categories AUB-E, and perhaps AUB-C, of the FIGO PALM-COEIN classification of causes \[[@CR12]\]. Eligible women were only excluded if they had contraindications to combined oral contraceptives. Ethics approval was obtained from the Family Planning NSW Ethics Committee (Ethics Committee application reference number R2012-07).

Recruitment {#Sec4}
-----------

Women were recruited from the Sydney Centre for Reproductive Health Research database, Facebook and radio advertisements. Women who identified themselves as having HMB were telephone screened by an experienced research assistant. If their responses indicated that they were likely to have objective HMB, the Research Coordinator (RC) discussed the MBL study. Interested women were sent written information about the study and contacted 1 week later. If willing to participate, an appointment was made to attend the Research Centre where the RC provided study details and obtained written informed consent.

Study procedures {#Sec5}
----------------

### Run-in period {#Sec6}

Women who had given consent completed the online HMB questionnaire \[[@CR17]\] (attachment 1), a detailed validated questionnaire looking at various aspects of quality of life before entering and on completion of the study \[[@CR17]\]. Blood was taken in standard manner for haemoglobin estimations, transferrin saturation, serum iron and ferritin. Women were given verbal and written detailed instructions for MBL collection and provided with cotton pads, tampons and wipes suitable for MBL estimations, collection bags, cold packs and cold boxes. Participating women were asked to collect all used sanitary protection for three menstrual periods without treatment (cycles 1, 2 and 3) and complete a paper diary entering the details of their bleeding and any symptoms that they experienced, as well as the use of all sanitary protection. Treatment with oestradiol-17β 1.5 mg--nomegestrol acetate 2.5 mg monophasic COC tablets on a 24 + 4 day regimen (MSD/Merck; marketed in Australia as Zoely) was started on day 1 of the next period (cycle 4). This menstrual period (cycle 4) was not included in the formal analysis of the following three 'during treatment' cycles (cycles 5, 6 and 7).

In addition to the paper diary, recording days of bleeding and number of tampons and pads used each day, they also completed a chart on which they indicated the size of any 'clot' passed, the amount of blood that was lost in the toilet according to the icon on the chart, any blood lost in staining of undergarments, etc.

All tampons and pads used for each of three consecutive menses were sent at the end of each menses by courier to the Queen Elizabeth II Research Institute for Mothers and Infants for the MBL estimations, which were carried out by the alkaline haematin method, which has been applied in research studies in our laboratory for over 35 years \[[@CR18]\]. All costs of sanitary protection, transport materials and couriers were covered by the project.

Sample size and analysis {#Sec7}
------------------------

The primary efficacy endpoint was the proportion of women with a reduction ≥50% from baseline in objectively measured menstrual blood loss. Secondary efficacy endpoints were the number and proportion of cycles with a normal blood loss (≤80 mL, and the total group reduction in measured blood loss).

We planned to recruit 20 women to the pilot study. Based on results of previous studies with ethinyl-oestradiol-based combined oral contraceptives, we assumed that 50% of the women would achieve a reduction ≥50% in mean blood loss. With 20 women in the study, the resulting confidence interval for this percentage has a precision of ±22%. This pilot study would then indicate that the percentage of women with a complete response would be at least 28%. A sample size of 20 would also have a power greater than 80% to detect a reduction of 100 mL in objectively measured MBL over a 3-month reference period assuming *α* = 0.05 and standard deviation of 100 mL (based on studies with the oestradiol-valerate--dienogest COCP, Qlaira, Bayer Healthcare). 'Qlaira' is the only other oestradiol-17β-based COCP studied for its effect on HMB.

The mean of continuous measures of MBL and iron metabolism parameters were calculated for the three cycle pre-treatment phase (cycles 1, 2 and 3) and the 'during treatment phase' (cycles 5, 6 and 7). We then calculated the percent reduction in MBL by comparing the mean for the pre-retreatment phase with that for the treatment phase.

The continuous measures of MBL and iron metabolism parameters were analysed using the signed-rank test due to the small sample size and expected skewness of the measures. Categorical responses to questions before and during treatment were compared using McNemar's test for paired proportions.

We calculated an exact 95% confidence interval for the primary outcome and proportion of women with a reduction ≥50% from baseline in MBL. The difference between pre-treatment and during treatment in continuous measures of MBL and the iron metabolism parameters were analysed using the signed-rank test due to the small sample size and expected skewness of the measures. *t* tests and 95% confidence intervals of the difference in the means of these continuous measures were also calculated. Categorical responses to questions before and after treatment were compared using McNemar's test for paired proportions. All analyses were carried out using SAS v9.3 (SAS Institute).

Results {#Sec8}
=======

Forty-three women, mean age 35.7 years (range 20--48), were enrolled in this pilot study, of whom 31 either withdrew or were ineligible due to underlying pathology or otherwise not complying with entry criteria (Fig. [1](#Fig1){ref-type="fig"}). Twelve women entered the treatment phase and commenced the E~2~/nomegestrol acetate 24/4 combined pill treatment on the first day of their next menses and continued treatment for three cycles. Ten women continued to collect their used sanitary protection for the following four cycles (including the three full-treatment cycles 5, 6 and 7) and send them by courier to the University of Sydney as previously described. One subject was discontinued after taking two cycles of E-17β-Nomac because of a significant rise in blood pressure and therefore did not collect the seventh menstrual period. Another subject did not collect in menstrual period 5 as she was travelling overseas. Their results are reported separately.Fig. 1Study flow chart

All women showed considerable variation in MBL during their three run-in periods (Table [1](#Tab1){ref-type="table"}). On average, 70% of individual cycles had MBL greater than 80 mL. This meant that only 30% of pretreatment menstrual periods had an MBL of \<80 mL while 97% of periods during the treatment phase were less than 80 mL. All women with complete MBL measurements had greater than 50% reduction in MBL on treatment (exact 95% confidence interval for proportion with MBL reduction greater than 50%: 69 to 100%).Table 1Individual subject's measured menstrual blood loss (mL) per study cyclePretreatmentCOCP startTreatment cyclesSubjectCycle 1 (mL)Cycle 2 (mL)Cycle 3 (mL)Cycle 4 (mL)Cycle 5 (mL)Cycle 6 (mL)Cycle 7 (mL)199.560.8128.756.69.924.5Discontinued273.9208.4150.035.118.916.925.3342.1318.379.428.714.717.228.7487.665.065.092.833.841.925.05127.683.6131.0194.3027.718.16280.988.458.680.433.242.061.57259.1222.7244.4109.060.413.396.8892.860109.540.96.421.620.5984.0130.432.984.66.438.331.410230.5104.4169.6189.10001192.5212.3218.8170.2Not collected overseas51.261.212137.423.092.347.043.524.229.4Started E~2~/NOMAC on the first day of bleeding in this cycle

The mean percent reduction in MBL between pretreatment and during treatment cycles was 76.9% and the median was 79% (with a range of 53.7 to 100%) (Table [2](#Tab2){ref-type="table"}). The two subjects with only two post-treatment collections also had 81.2 and 79.9% reduction in MBL respectively. The median absolute reduction in monthly blood loss was 98 mL per period per subject with a range of 39--185 mL. Individual reductions in MBL between pre- and during treatment are shown in Fig. [2](#Fig2){ref-type="fig"}. In 33 of 34 treatment cycles, blood loss had reduced to within the normal range (\<80 mL).Table 2Comparison of mean and median monthly reduction in MBL for the group between the pre-treatment phase and the treatment phaseVariableNumberMean (mL)Std Devn (mL)Median (mL)Minimum (mL)Maximum (mL)Mean (mL) before treatment (cycles 1, 2 and 3)10128.452.0128.472.5242.1Mean (mL) on treatment (cycles 5, 6 and 7)1026.616.322.90.056.8Difference in means (before treatment compared to on-COC)10101.949.397.939.0185.2Percent reduction1076.913.879.053.7100.0Ninety-five percent confidence interval for difference in means (66.6, 137.1), *P* = 0.0001 (paired *t* test), *P* = 0.002 (signed-rank test). Ninety-five percent confidence interval for percent reduction (67.0, 86.8), *P* \< 0.0001 (one sample *t* test), *P* = 0.002 (signed-rank test) Fig. 2Mean paired pretreatment MBL for three pre-treatment cycles and three cycles on treatment with E~2~/NOMAC for 12 individual women

Effect of treatment on quality of life {#Sec9}
--------------------------------------

There was no statistically significant difference in reported QoL during treatment in regard to pain, effect on leisure activities or effect on sex life in those women who had sexual relationships during menstruation.

The only significant change shown in iron parameters was an increase in mean ferritin levels (Table [3](#Tab3){ref-type="table"}).Table 3Iron study results before commencing treatment and on completion of treatmentNumberMean95% confidence intervalMedianMinimumMaximum*P* value (*t* test)*P* value (signed rank)HB before treatment10135.1134.0123148HB end of treatment10137.0136.5125150Difference (on-before)101.9−3.1, 6.73.5−11120.470.56Transferrin before treatment104.913.052.423Transferrin on treatment104.822.852.323.3Difference (on-before)10−0.09−0.25, 0.07−0.05−0.60.30.240.28TIBC before treatment1064.2665476TIBC on treatment1062.4635272Difference (on-before)101.8−1.5, 5.11−6120.240.34*T*-saturation before treatment100.2970.320.110.49*T*-saturation on treatment100.2680.2850.090.4Difference (on-before)10−0.029−0.128, 0.070−0.095−0.150.20.530.54Ferritin before treatment1028.127744Ferritin on treatment104145.51763Difference (on-before)1012.95.9, 19.912.5032*0.0020.004*A value of *P* \<0.05 was taken as significant. This includes all values in italics

Discussion {#Sec10}
==========

The E~2~/Nomac combined pill was extremely efficient at significantly reducing MBL in all 12 women with objectively measured HMB. The treatment drug produced a 50% or greater reduction in MBL in virtually all women. In all but one treated cycle blood loss was well below the established upper norm of 80 mL. If extrapolated over a 3-month (three menstrual periods) reference period, this would have resulted in an overall total menstrual blood loss volume reduction of 305.4 mL "saved" for each woman every 3 months during E~2~/Nomac treatment or a gross total around 1222 mL "saved" annually. This demonstrates a huge additional requirement for iron intake per year by these women when they are without treatment.

It was surprising that the post-treatment questionnaire found that our E~2~/Nomac treatment, which reduced blood loss to well below the upper limit of normal, had little effect on the subject's QoL compared to pretreatment, possibly due to the small number of subjects and the limited duration of the study. The results suggest that pain with menstruation was not significantly ameliorated, although pain scores were not specifically investigated. A trend for improvement in coping with leisure activities and sex life was also apparent, although not statistically significant.

There was a significant increase in serum ferritin levels following treatment but no other significant change in iron parameters. The improvement in ferritin levels clearly reflects the very significant reduction in MBL for all subjects. The failure of the other iron indices to show a significant difference probably relates to the short 3-month treatment period and the small numbers in this pilot study. However, caution needs to be used in interpretation of any hypothesis testing with such small numbers.

The pre-treatment questionnaire indicated that 50% of women with demonstrated HMB experienced a significant adverse effect on QoL parameters during menstruation. An efficient medical treatment which significantly reduces blood loss (to a greater degree than any other oral therapy) and has minimal side effects is an important addition to the range of therapies available for managing the HMB problem.

Our result of a 79.6% mean reduction in MBL compared very favourably with other studies which also used objective quantification of MBL during medical treatments of HMB. A number of studies have reported on the effect of combined oral contraceptives (COCP) on HMB. Only four have investigated the efficacy of COCPs using objectively measured MBL \[[@CR18]--[@CR21]\]. The first randomised study demonstrated a mean reduction of 43% in MBL over two cycles of treatment with a 30-μg EE COCP in 12 women \[[@CR18]\]. The second larger randomized study of 56 women reported a 35% mean reduction in MBL over 12 months of treatment with a 30-μg EE COCP \[[@CR19]\]. An early, non-randomised trial in 1971 of 164 women \[[@CR20]\], which also studied objective measurement of MBL, found that a high-dose (50--75 μg EE) COCP reduced mean MBL by 52.6%. The fourth study which trialled a dienogest/estradiol valerate combined pill (this was the first HMB study with an oestradiol-17β-based COCP) in a much larger study (*n* = 231) over 12 months reported a mean reduction of MBL of 69.4% (median 79.2%) \[[@CR21]\] only slightly less than in the present trial with E~2~/Nomac. This present E~2~/Nomac study showed a mean reduction of 76.9% (median 79.0%). These two studies suggest that oestradiol-17ß-based COCs may be in a separate COCP class with respect to their therapeutic benefit on HMB. It is probable that oestradiol-17β combined with either Nomac or dienogest has a more favourable response on the endometrium in producing menstrual period haemostasis than ethinyl-oestradiol combinations.

A previous contraceptive study of women without HMB treated with E~2~/Nomac found that 30% had completely absent withdrawal bleeding at the end of 12 months \[[@CR22]\]. In contrast, a study comparing a COCP using a 24/4 regimen with the same COCP on a 21/7-day regimen \[[@CR23]\] found no difference in bleeding patterns suggesting that the improvement in HMB in our study was not due to the 24/4 regimen but resulted from the oestradiol-17β-based formulation of the COCP.

This present study was a pilot trial to ascertain whether combining oestradiol-17β with nomegestrol acetate in a monophasic regimen would be effective in reducing MBL in women with AUB-E with objectively confirmed HMB. The main weakness lies in the small number of women we were able to recruit with objective HMB caused by AUB-E, due to changing social and cultural dynamics. E~2~/Nomac may be as effective in reducing MBL as the oestradiol valerate/dienogest combination, but further studies in larger numbers of women will be necessary to confirm this. Hypothesis testing is not possible with limited numbers of subjects. Larger studies may well also run into problems of recruitment of large numbers of well-investigated women, due to general reluctance of both investigators and women to collect all used sanitary protection. Although pictorial blood loss assessment charts are less accurate in objective measurement of menstrual blood loss than in alkaline haematin method, they are accurate enough for sound comparison of pre-and intra-treatment assessments, subject to meticulous care with collections and assessment by the same investigator. This would be a less expensive option, and recruitment is likely to be easier. We would suggest that any future trial should ideally compare, in a randomized manner, this E2/Nomac combination with a widely used 30-μg ethinyl-oestradiol-containing combination. A total of 50 enrolled women with objectively measured menstrual blood loss studied over three pre-treatment months and a minimum of three intra-treatment months will offer substantially increased power compared with the present study. This should be sufficient to test the hypothesis that the E2-based COCs are more effective treatments for HMB than for ethinyl-oestradiol-based COCs.

Conclusions {#Sec11}
===========

This pilot study indicates that the E~2~/Nomac COCP is likely to provide a useful new option for treating HMB in women who have probable primary endometrial causes of the abnormal bleeding (AUB-E). This effect may be greater than that seen with women using ethinyl-oestradiol-based COCPs.

We are indebted to Dr Frank Manconi who carried out all the blood loss measurements.
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